Raltegravir Potassium Patent Expiration
Raltegravir Potassium is Used for treating HIV infection by inhibiting integrase. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Raltegravir Potassium Patents
Given below is the list of patents protecting Raltegravir Potassium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Isentress | US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 03, 2023
(Expired) | Msd Sub Merck |
| Isentress | US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 03, 2023
(Expired) | Msd Sub Merck |
| Isentress |
US7169780 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 03, 2024
(Expired) | Msd Sub Merck |
| Isentress | US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Msd Sub Merck |
| Isentress |
US7217713 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Msd Sub Merck |
| Isentress | US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Msd Sub Merck |
| Isentress |
US7435734 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Msd Sub Merck |
| Isentress | US7754731 | Potassium salt of an HIV integrase inhibitor | Mar 11, 2029 | Msd Sub Merck |
| Isentress |
US7754731 (Pediatric) | Potassium salt of an HIV integrase inhibitor | Sep 11, 2029 | Msd Sub Merck |
| Isentress | US8771733 | Pharmaceutical composition containing an anti-nucleating agent | Jun 02, 2030 | Msd Sub Merck |
| Isentress | US8852632 | Pharmaceutical formulation containing a release rate controlling composition | Jan 28, 2028 | Msd Sub Merck |
| Isentress Hd | US10772888 | Solid pharmaceutical compositions containing an integrase inhibitor | Mar 30, 2032 | Msd Sub Merck |
| Isentress Hd | US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 03, 2023
(Expired) | Msd Sub Merck |
| Isentress Hd |
US7169780 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 03, 2024
(Expired) | Msd Sub Merck |
| Isentress Hd | US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Msd Sub Merck |
| Isentress Hd |
US7217713 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Msd Sub Merck |
| Isentress Hd | US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Msd Sub Merck |
| Isentress Hd |
US7435734 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Msd Sub Merck |
| Isentress Hd | US7754731 | Potassium salt of an HIV integrase inhibitor | Mar 11, 2029 | Msd Sub Merck |
| Isentress Hd |
US7754731 (Pediatric) | Potassium salt of an HIV integrase inhibitor | Sep 11, 2029 | Msd Sub Merck |
| Isentress Hd | US8771733 | Pharmaceutical composition containing an anti-nucleating agent | Jun 02, 2030 | Msd Sub Merck |
| Isentress Hd | US9649311 | Solid pharmaceutical compositions containing an integrase inhibitor | Oct 21, 2030 | Msd Sub Merck |
| Isentress Hd |
US9649311 (Pediatric) | Solid pharmaceutical compositions containing an integrase inhibitor | Apr 21, 2031 | Msd Sub Merck |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳